Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Respiratorius ABXSAT:RESP +1.31%34 3-1 Month Momentum % is 8.51% as of Aug. 14, 2026. GuruFocus rates XSAT:RESP with a GF Score™ of 34/100. Among 1,388 Biotechnology companies, Respiratorius AB ranks better than 73.85% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-14), Respiratorius AB's 3-1 Month Momentum % is 8.51%.
The industry rank for Respiratorius AB's 3-1 Month Momentum % or its related term are showing as below:
XSAT:RESP's 3-1 Month Momentum % is ranked better than 73.85% of 1388
companies
in the Biotechnology industry
Industry Median: -8.13
vs XSAT:RESP: 8.51
Respiratorius AB (XSAT:RESP) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Respiratorius AB 3-1 Month Momentum % Related Terms
XSAT:RESP vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Respiratorius AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Respiratorius AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Respiratorius AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Respiratorius AB's 3-1 Month Momentum % falls into.
Respiratorius AB (XSAT:RESP) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Respiratorius AB (XSAT:RESP) has a 3-1 Month Momentum % of 8.51% as of Aug. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Respiratorius AB and its competitors. According to the industry distribution chart, Respiratorius AB ranks #363 out of 1388 companies in the Biotechnology industry, placing it in the top 26.2%.
Is Respiratorius AB's 3-1 Month Momentum % too high?
Respiratorius AB's current 3-1 Month Momentum % is 8.51%. Based on the distribution chart, Respiratorius AB ranks #363 out of 1388 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Respiratorius AB has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Respiratorius AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Respiratorius AB ranks #363 out of 1388 companies for 3-1 Month Momentum %. This puts Respiratorius AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Respiratorius AB and its competitors. Respiratorius AB's current 3-1 Month Momentum % is 8.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Respiratorius AB stock overvalued right now?
Respiratorius AB (XSAT:RESP) has a current 3-1 Month Momentum % of 8.51%. The current 3-1 Month Momentum % is 8.51%. Respiratorius AB's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Respiratorius AB (XSAT:RESP), the current 3-1 Month Momentum % is 8.51% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
34GF Score
Get the complete analysis for XSAT:RESP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:RESP has been successfully added to your 
